サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1578213

急性興奮および攻撃性治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測

Global Acute Agitation And Aggression Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 231 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
急性興奮および攻撃性治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測
出版日: 2024年09月01日
発行: Value Market Research
ページ情報: 英文 231 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

急性興奮および攻撃性治療市場の世界需要は、2023年の48億5,000万米ドルから2032年にはほぼ80億2,000万米ドルの市場規模に達すると推定され、調査期間2024-2032年のCAGRは5.75%です。

急性興奮は、異常な運動活動の有無にかかわらず、内的緊張や不安の状態を指します。一方、急性攻撃性は、自傷や他害の可能性がある行動表現を意味します。急性興奮と攻撃性の治療とは、興奮と攻撃性を治すために患者に行われる医療行為にほかならないです。一般に、うつ病、双極性障害、アルコール依存症、ホルモンバランスの乱れ、自閉症、ストレス、神経障害などの原因によって、急性期の興奮や攻撃性が引き起こされます。急性の興奮や攻撃性の治療は、穏やかな感覚を取り戻すのに役立ちます。

市場力学

世界の急性興奮および攻撃性治療市場は、心理的疾患における焦燥・攻撃性診断の増加、心理的疾患の経済的負担の増加、認知を広めるための組織の形成により、人気を集めています。精神疾患患者の焦燥感や攻撃性の診断に対する考え方の変化や治療に対する意識の高まりが、世界の急性焦燥感・攻撃性治療市場の成長を促進すると思われます。さらに、急性焦燥・攻撃性の新規治療法の研究開発が市場成長を促進すると予想されます。精神疾患の増加、老年人口における認知症発症の増加、患者の焦燥感、抗精神病薬の処方の増加が、今後数年間の急性興奮および攻撃性治療市場の成長を後押ししています。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、急性興奮・攻撃性治療の世界市場における各セグメントを包括的に評価することもできます。急性興奮・攻撃性治療産業の成長と動向は、この調査への全体的なアプローチを提供します。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 急性興奮および攻撃性治療- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 世界の急性興奮および攻撃性治療市場分析：治療アプローチ別

  • 概要
  • 実績および予測データ分析
  • 行動的アプローチ
  • 環境的介入
  • 薬理学的アプローチ（薬物）（ロラゼパム、クロルプロマジン、クエチアピン、ドロペリドール、オランザピン、ジプラシドン、その他）

第6章 世界の急性興奮および攻撃性治療市場分析：適応症別

  • 概要
  • 実績および予測データ分析
  • 統合失調症
  • 認知症
  • 双極性障害
  • うつ病
  • 薬物誘発性興奮と攻撃性
  • アルコール離脱
  • その他

第7章 世界の急性興奮および攻撃性治療市場分析：投与経路別

  • 概要
  • 実績および予測データ分析
  • 経口
  • 筋肉内
  • その他

第8章 急性興奮および攻撃性治療の世界市場分析：エンドユーザー別

  • 概要
  • 実績および予測データ分析
  • 病院・外来手術センター
  • 精神科医療施設
  • その他

第9章 急性興奮および攻撃性治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米セグメント別
    • 北米国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州セグメント別
    • 欧州国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • アジア太平洋地域セグメント別
    • アジア太平洋地域国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカセグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカセグメント別
    • 中東・アフリカ国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第10章 急性興奮および攻撃性治療企業の競合情勢

  • 急性興奮・攻撃性治療市場の競合
  • 提携／協力／合意
  • 合併・買収
  • 新製品の発売
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Eli Lilly And Company
  • Pfizer Inc.
  • Otsuka Holdings
  • GlaxoSmithKline
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • Bausch Health Companies Inc.
  • Apotex Inc.
  • Aurobindo Pharma
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Approach (USD MN)
  • Behavioral Approaches Market Sales By Geography (USD MN)
  • Environmental Interventions Market Sales By Geography (USD MN)
  • Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Market Sales By Geography (USD MN)
  • Analysis By Indication (USD MN)
  • Schizophrenia Market Sales By Geography (USD MN)
  • Dementia Market Sales By Geography (USD MN)
  • Bipolar Disorder Market Sales By Geography (USD MN)
  • Depression Market Sales By Geography (USD MN)
  • Drug-induced Agitation and Aggression Market Sales By Geography (USD MN)
  • Alcohol Withdrawal Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intramuscular Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End User (USD MN)
  • Hospitals & Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Psychiatric Care Facilities Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Acute Agitation And Aggression Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Acute Agitation And Aggression Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Acute Agitation And Aggression Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Approach
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By End User
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Approach (USD MN)
  • Behavioral Approaches Market Sales By Geography (USD MN)
  • Environmental Interventions Market Sales By Geography (USD MN)
  • Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Market Sales By Geography (USD MN)
  • Global Market Analysis By Indication (USD MN)
  • Schizophrenia Market Sales By Geography (USD MN)
  • Dementia Market Sales By Geography (USD MN)
  • Bipolar Disorder Market Sales By Geography (USD MN)
  • Depression Market Sales By Geography (USD MN)
  • Drug-induced Agitation and Aggression Market Sales By Geography (USD MN)
  • Alcohol Withdrawal Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Intramuscular Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End User (USD MN)
  • Hospitals & Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Psychiatric Care Facilities Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11218412

The global demand for Acute Agitation And Aggression Treatment Market is presumed to reach the market size of nearly USD 8.02 Billion by 2032 from USD 4.85 Billion in 2023 with a CAGR of 5.75% under the study period 2024-2032.

Acute Agitation refers to the state of inner tension or unease with or without abnormal motor activity. While acute aggression signifies a behavioural expression with the potential to self-harm or harm others. Acute agitation and aggressive treatment are nothing but the medical care given to a patient to get cured of agitation and aggression. Generally, acute agitation and aggression are caused in an individual due to reasons like depression, bipolar disorder, alcohol dependency, hormonal imbalances, autism, stress, and neurological disorders. Acute agitation and aggression treatment can help in restoring the sense of calm.

MARKET DYNAMICS

The global acute agitation and aggression treatment market is gaining popularity owing to the rise in the agitation and aggression diagnosis in psychological illnesses, the increase in the economic burden of psychological illness, and the formation of an organization to spread awareness. Altering attitudes toward agitation and aggression diagnosis among mentally ill patients and an increase in awareness about treatments are likely to fuel the global acute agitation and aggression treatment market growth. Additionally, research and development of novel treatments for acute agitation and aggression are expected to drive market growth. The rise in mental illness, increase in dementia incidences among the geriatric population, the rush in agitation in patients, and an increase in prescriptions of anti-psychotics are boosting the growth of the acute agitation and aggression treatment market in the forthcoming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Agitation And Aggression Treatment. The growth and trends of Acute Agitation And Aggression Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Acute Agitation And Aggression Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Approach

  • Behavioral Approaches
  • Environmental Interventions
  • Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others)

By Indication

  • Schizophrenia
  • Dementia
  • Bipolar Disorder
  • Depression
  • Drug-induced Agitation and Aggression
  • Alcohol Withdrawal
  • Others

By Route of Administration

  • Oral
  • Intramuscular
  • Others

By End User

  • Hospitals & Ambulatory Surgical Centers
  • Psychiatric Care Facilities
  • Others
  • Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Global Acute Agitation And Aggression Treatment Market Report market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Agitation And Aggression Treatment market include Eli Lilly And Company, Pfizer Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Apotex Inc., Aurobindo Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ACUTE AGITATION AND AGGRESSION TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Approach
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Route of Administration
    • 3.7.4 Market Attractiveness Analysis By End User
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY TREATMENT APPROACH

  • 5.1. Overview By Treatment Approach
  • 5.2. Historical and Forecast Data Analysis By Treatment Approach
  • 5.3. Behavioral Approaches Historic and Forecast Sales By Regions
  • 5.4. Environmental Interventions Historic and Forecast Sales By Regions
  • 5.5. Pharmacologic Approaches (Drugs) (Lorazepam, Chlorpromazine, Quetiapine, Droperidol, Olanzapine, Ziprasidone, Others) Historic and Forecast Sales By Regions

6. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY INDICATION

  • 6.1. Overview By Indication
  • 6.2. Historical and Forecast Data Analysis By Indication
  • 6.3. Schizophrenia Historic and Forecast Sales By Regions
  • 6.4. Dementia Historic and Forecast Sales By Regions
  • 6.5. Bipolar Disorder Historic and Forecast Sales By Regions
  • 6.6. Depression Historic and Forecast Sales By Regions
  • 6.7. Drug-induced Agitation and Aggression Historic and Forecast Sales By Regions
  • 6.8. Alcohol Withdrawal Historic and Forecast Sales By Regions
  • 6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1. Overview By Route of Administration
  • 7.2. Historical and Forecast Data Analysis By Route of Administration
  • 7.3. Oral Historic and Forecast Sales By Regions
  • 7.4. Intramuscular Historic and Forecast Sales By Regions
  • 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY END USER

  • 8.1. Overview By End User
  • 8.2. Historical and Forecast Data Analysis By End User
  • 8.3. Hospitals & Ambulatory Surgical Centers Historic and Forecast Sales By Regions
  • 8.4. Psychiatric Care Facilities Historic and Forecast Sales By Regions
  • 8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ACUTE AGITATION AND AGGRESSION TREATMENT COMPANIES

  • 10.1. Acute Agitation And Aggression Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF ACUTE AGITATION AND AGGRESSION TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Eli Lilly And Company
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Pfizer Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Otsuka Holdings
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. GlaxoSmithKline
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. H. Lundbeck A/S
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Johnson & Johnson
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Teva Pharmaceutical Industries Ltd.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Amneal Pharmaceuticals LLC
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Sun Pharmaceutical Industries Ltd.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. F. Hoffmann-La Roche Ltd
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Bausch Health Companies Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Apotex Inc.
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. Aurobindo Pharma
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies